Patents by Inventor HANEN KHABOU

HANEN KHABOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
    Patent number: 11723988
    Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 15, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
    Inventors: Deniz Dalkara, Hanen Khabou, José-Alain Sahel, Thierry Leveillard, Jens Duebel
  • METHODS OF EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN THE CONE PHOTORECEPTORS OF A SUBJECT COMPRISING THE SUBRETINAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9-DERIVED VECTOR
    Publication number: 20210268125
    Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.
    Type: Application
    Filed: October 22, 2018
    Publication date: September 2, 2021
    Inventors: DENIZ DALKARA, HANEN KHABOU, JOSÉ-ALAIN SAHEL, THIERRY LEVEILLARD, JENS DUEBEL